Please use this identifier to cite or link to this item:
|Title:||Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: Correlation with outcomes||Authors:||Grim, S.A.
|Issue Date:||Mar-2012||Citation:||Grim, S.A., Berger, K., Teng, C., Gupta, S., Layden, J.E., Janda, W.M., Clark, N.M. (2012-03). Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: Correlation with outcomes. Journal of Antimicrobial Chemotherapy 67 (3) : 707-714. ScholarBank@NUS Repository. https://doi.org/10.1093/jac/dkr511||Abstract:||Objectives: We sought to determine the impact of timing of appropriate antifungal therapy, as assessed by susceptibility results, on patient survival. Methods: Patients ≥16 years of age with first episodes of candidaemia during 2001-09 were included. Clinical data were collected retrospectively, including time to appropriate antifungal therapy and patient survival. Results: The study population included 446 patients [243 (54%) female, mean age 53 years] with candidaemia, 380 (85%) of whom had antifungal susceptibility data. Candida albicans was the most common pathogen (221, 50%) followed by Candida glabrata (99, 22%), Candida parapsilosis (59, 13%), Candida tropicalis (48, 11%) and Candida krusei (6, 1%). Appropriate antifungal therapy consisted of fluconazole (177, 40%), an echinocandin (125, 28%), amphotericin B (41, 9%) and voriconazole (6, 1%); 97 (22%) failed to receive appropriate antifungal therapy. The 30 day mortality was 34% (151/446) and there was no clear relationship between time from positive culture to receipt of appropriate antifungal therapy and 30 day survival. On multivariable Cox regression, increased APACHE II score [hazard ratio (HR) 1.11, 95% CI 1.09-1.13, P,0.001], cirrhosis (HR 2.15, 95% CI 1.48-3.13, P,0.001) and HIV infection (HR 2.03, 95% CI 1.11-3.72, P=0.02) were independent predictors of mortality. A secondary analysis requiring patients in the early treatment group to have received ≥24 h of effective antifungal therapy did show a significant mortality benefit to receiving antifungal treatment within 72 h of a positive blood culture being drawn (30 day mortality for early treatment: 27% versus 40%, P=0.004; HR for mortality with delayed treatment on multivariable analysis: 1.41, 95% CI 1.01-1.98, P=0.045). Conclusions: Candida bloodstream infection is associated with high mortality, despite timely receipt of appropriate antifungal therapy. © The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.||Source Title:||Journal of Antimicrobial Chemotherapy||URI:||http://scholarbank.nus.edu.sg/handle/10635/106460||ISSN:||03057453||DOI:||10.1093/jac/dkr511|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Nov 15, 2019
WEB OF SCIENCETM
checked on Nov 15, 2019
checked on Nov 9, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.